ABSTRACT
INTRODUCTION:
Global prevalence of childhood Attention Deficit Hyperactivity Disorder (ADHD) is reported to be between 5-10% [1-3], with two-thirds of all childhood ADHD cases persisting into adulthood [4, 5] . Furthermore, adult ADHD is overrepresented in substance use disorder (SUD) populations and, subject to the sampling methodology applied, prevalence estimates range from 14-44% [6-10], which is considerably higher than the 3-7% observed in the community [11] [12] [13] [14] .
ADHD is an important risk factor for SUDs [15, 16] . Research measuring adult ADHD symptoms has demonstrated that people with ADHD are at a four-fold greater risk of SUD than people without ADHD, which is exacerbated if ADHD is not managed effectively [6, 12, 17] . In some studies, these associations remain after controlling for comorbid conduct disorder (CD) effects [15, 18, 19] .
To date, most studies in this area have compared the association between ADHD and the presence of SUD in general. Comorbid ADHD and SUD has been observed to exacerbate a number of maladaptive SUD outcomes such as earlier drug use initiation, more severe SUD, increased psychiatric comorbidities, hospitalisations, suicide attempts, and HIV-risk behaviours [18, 20, 21] ; thus making the treatment and management of SUD in clinical settings more challenging and less effective [22] [23] [24] . The potential effects of concomitant adult ADHD according to drug-specific SUD complexity and chronicity remain unclear, however these specific factors are potentially predictive of poor treatment adherence, treatment setting effectiveness, slower SUD remission, and greater risk of SUD relapse [21, 22, 24 ,25] making their examination important for treatment optimisation in these comorbid patients [26] . The few studies in this area have almost exclusively focussed on 5 RUNNING HEAD: ADHD and Substance Use Disorder Complexity small (often n<100) patient samples and have not undertaken drug-specific sub-group analyses, or controlled for other potential modifying risk factors [27] .
The aims of this study were to: i) estimate the prevalence of adult ADHD symptoms in Australian SUD populations; ii) assess the association between ADHD symptoms and current SUD for different drug types and for polydrug dependence; and iii) explore the effect of concurrent adult ADHD symptoms on the chronicity of SUD in treatment-seeking SUD patients.
METHODS:
This study used data from the Australian sites of the International ADHD in Substance use disorders Prevalence (IASP) study; the patient characteristics and design of which is described in further detail elsewhere [28] .
Study Design
A cross-sectional survey was administered to a convenience sample of adults (≥18years) receiving treatment for SUD in Western Australian (WA) and New South Wales (NSW) metropolitan drug and alcohol treatment centres between 1 st September, 2010 and 31 st August, 2011.
Study Sample
The sample comprised 489 adults attending drug and alcohol treatment centres for clinicallydiagnosed SUD across two Australian States (187 participants from three residential and five outpatient centres in WA and 302 from four residential and four outpatient centres in NSW).
Outpatients (7%;n=34) were receiving either methadone maintenance or psychosocial treatments. Inclusion was restricted to adult participants (≥18 years) receiving active clinical SUD treatment whose current treatment episode began less than six months (≤180 days) 6 RUNNING HEAD: ADHD and Substance Use Disorder Complexity before the administration of the survey. A small fraction of individuals (1.4%) that initiated treatment prior to six months, with a reported SUD relapse requiring active treatment within six months of the survey were also included. This inclusion criterion was employed to coincide with the six-month Adult ADHD Self-Report Scale (ASRS) symptom assessment period [29] , documented as the most reliable period of self-reported ADHD symptoms [30] and to confirm that no patient had achieved the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-R) and the DSM-5 analogous "full SUD remission" and the specified "in sustained remission" criteria [31, 32] , therefore retaining their comorbid status. All participants were volunteers and were reimbursed AUD$ 20 for participation.
Assessments
The study questionnaire was developed by the IASP Study [28] and assessed patient sociodemographics, drug use history, current adult ADHD screening status, ADHD symptom onset, and reported history of ADHD clinical diagnosis. Patient drug-specific use was assessed through self-report of age of onset, current clinically diagnosed drug dependence requiring treatment, and previous total years of problematic regular use.
Patients were screened for adult ADHD symptoms using the validated ASRS six-item (ASRS-6) dichotomous screener scoring method of Kessler et al. [29] which requires endorsement of four out of six current ADHD symptoms and has been previously validated in SUD populations [33] [34] [35] . ASRS-6 screening was conducted a median of 18 days (interquartile range(IQR)=7-36) after SUD treatment commencement in accordance with optimal ADHD screening periods between 14-28 days of abstinence in SUD adults [36] [37] [38] , reducing the possibility of false-positives due to intoxication or withdrawal symptom overlap.
Participants were asked to report the age of impairment onset due to ADHD symptoms.
Previous clinical ADHD diagnoses in childhood and/or as an adult were assessed through participant self-report.
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The probable presence or absence of concurrent adult ADHD in SUD patients, herein referred to as ADHD-Screened Positive (ADHD-SP) and ADHD-Screened Negative (ADHD-SN), was identified using the ASRS-6 with an age of onset criteria (AOC) threshold of <12 years, an empirically supported threshold in accordance with the DSM-5 adult ADHD diagnosis requirements [32] . Previous investigation has shown that 95% of ADHD and only less than 10% of mood disorders onset prior to 12 years [39] ; therefore this AOC threshold was set to minimise potential misclassification bias due to shared symptom presentation between ADHD and mood disorders, documented to create an inflated risk of false positives from increased comorbid prevalence of these disorders in SUD populations [33, 40] .
Additionally, this AOC threshold aids in differentiating between shared ADHD and SUD symptoms [38] , increasing confidence that the reported ADHD symptoms were antecedent to adolescence, where the vast majority of SUDs and mood disorders onset is observed [39, 40] . 
Statistical Methods
All analyses were conducted using SPSS Version 20.0. All primary tests were two-tailed with significance set at p<0.05. Additionally, Simes' correction (P Simes :p<0.01) was applied to adjust the p-value for multiple testing on all primary tests (i.e. Tables 2-5); Simes' method has been asserted to control for type I error while avoiding the potential for overcorrection affiliated with the Bonferroni method [42, 43] . RUNNING HEAD: ADHD and Substance Use Disorder Complexity Descriptive statistics were calculated for all variables. Crude (unadjusted) comparative analyses (independent samples t-tests and chi-square) were initially performed comparing continuous and categorical outcomes respectively, between ADHD-SP and ADHD-SN groups. Crude ORs (95%CIs) were calculated by univariate logistic regression for all binary outcome variables.
The association between concomitant ADHD symptom status (ADHD-SP versus ADHD-SN) and SUD complexity and chronicity was estimated separately for each drug type while controlling for a range of sociodemographic, clinical, and behavioural characteristics.
Multivariate logistic regression modelling was used to determine the association between ADHD and drug-specific current SUD, SUD history, and SUD comorbidity index. For significant associations from collapsed binary SUD history variables, additional modified loglinked Poisson regression models utilising robust sandwich variance were fitted to uncorrelated ordinal factor variables for SUD duration, predicting binary ADHD screening status as outlined previously by Zou (2004) [44] .
All regression models adjusted for age, gender, ethnicity, education level, marital status, history of traumatic brain injury, living arrangements, and offending history. Covariates were selected due to demonstrated or likely influence on the association between ADHD and SUD [18, 45] . Originally, a smaller nested-model including age, gender, ethnicity and education level was fit, however the larger model was a more parsimonious fit [46] for the outcomes assessed. It was planned to adjust for self-reported CD and ODD diagnoses, as both variables represent common covariates in comorbid ADHD and SUD research [47] [48] [49] .
However, these factors were not included in the regression models due to low study sample prevalence (0.8% and 0.4%, respectively).
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RESULTS:
Characteristics of study participants overall and by ADHD subgroup are displayed in Table 1 
ADHD and current SUDs
A summary of the reported current SUDs at the time of questionnaire completion is presented in Table 2 . Primary multivariate logistic regression adjusting for potential confounders indicated an increased odds for the ADHD-SP group compared to the ADHD-SN group of having SUDs for amphetamine and cannabis (Table 2 ). After Simes' correction (P Simes :p<0.01) was applied, only the association for amphetamine SUD remained significant (p=0.007).
In total, 77.7% (n=380) of the sample reported multiple current SUDs at the time of the study, with 26.4% (n=129) reporting four or more SUDs concurrently. Primary multivariate logistic regression modelling revealed that, compared to the ADHD-SN group, the ADHD-SP group was significantly more likely to have four or more concurrent SUDs (OR=2.06; 95%CI:1.03-4.11). However, after Simes' correction, this association did not remain significant (p=0.042).
Prior SUD History Reported
Prior SUD history for each drug is summarised in Table 2 . A total of 476 participants (97.3%) reported multiple prior SUDs, with the median number of SUDs being 5 (range 1-11). RUNNING HEAD: ADHD and Substance Use Disorder Complexity Primary multivariate logistic regression indicated significant positive associations between ADHD screening status and prior SUD history for heavy alcohol use, amphetamine, opiates other than heroin or methadone, benzodiazepines, and ecstasy (Table 2) . After Simes' correction, only the association for heavy alcohol use (p=0.007) and amphetamine (p=0.003) SUD history remained significant. <Table 2>
ADHD Status and SUD Duration
The estimated prevalence risk ratios (PRR) from modified Poisson regression analysis describing the association between ADHD screening status and SUD duration are presented in Table 3 . Primary analyses indicated that ADHD-SP patients were significantly more likely to report short (i.e. 1-2 years) durations of SUD for ecstasy as well as short and long (i.e. ≥5 years) durations of SUD for opiates other than heroin or methadone. In addition, the ADHD-SP group was significantly more likely to report moderate (i.e. 3-4 years) and long durations of benzodiazepines SUD as well as short, moderate, and long durations of amphetamine SUD. The ADHD-SP group was also significantly more likely to report long durations of SUD for heavy alcohol use (Table 3) . After Simes' correction, only the risk for moderate durations of benzodiazepines and amphetamine SUDs as well as long durations for opiates other than heroin or methadone, heavy alcohol use, and amphetamine SUDs remained significant. <Table 3>
DISCUSSION:

Prevalence of probable adult ADHD in SUD patients
Just under half (44.0%) of the adult patients with SUD in the current study screened positive for current ADHD symptoms present prior to 12 years of age, representing a seven-fold increase compared to a recent ASRS screening prevalence estimate in an Australian representative community sample (6.2%) [11] . The screening prevalence estimate observed RUNNING HEAD: ADHD and Substance Use Disorder Complexity in our sample was at the upper range limit when compared to other published studies using the ASRS in SUD populations (range 8-44%) [7] [8] [9] [10] 33] . This large prevalence variability is possibly due to a variety of potential influences such as cross-national variation in screening methodology, SUD treatment availability, or divergent clinical SUD characteristics and drugspecific SUD distribution of the patients seeking treatment. It is not possible to identify the main influences using the current methodology. However, as these comparative research studies utilised no AOC threshold, our AOC of 12 years suggests that the high ADHD screening prevalence observed in our study is not due to less conservative ADHD screening methodology. The ASRS-6 has been shown to have good sensitivity (84-88%) in identifying ADHD in treatment-seeking SUD patients, however ASRS-6 screening alone resulted in a small amount of false positives and slightly inflated prevalence estimates when compared to a 'gold-standard' clinical diagnostic interview in the IASP study [35] . Therefore, although accurate in the majority of cases, the ARSR-6 ADHD status in the current study indicates the presence of ADHD symptoms and should not be interpreted as a DSM-IV or DSM-5 diagnostic indication of adult ADHD prevalence in treatment-seeking SUD patients.
ADHD screening status and SUD complexity and chronicity
In this population of treatment-seeking SUD patients, compared to the ADHD-SN group, the ADHD-SP group was approximately two times more likely to have a current amphetamine SUD and a reported history of amphetamine and alcohol SUDs. Other studies have observed similar positive associations between ADHD and SUD in general [15, 50] reported that ADHD status is positively associated with increased frequency of the use of cocaine, other illicit psychostimulants [52] , benzodiazepines, and opiates [48] compared to controls. It is possible that neurobiological differences, impaired executive functioning, and elevated impulsivity contribute to increased SUD complexity and chronicity in individuals with ADHD compared to normal controls [53] [54] [55] [56] [57] . Although it is likely that comorbid ADHD RUNNING HEAD: ADHD and Substance Use Disorder Complexity increases vulnerability to drug and polydrug dependence in general, the drug-specific pattern of SUD increase in treatment-seeking SUD/ADHD-SP above what is seen in SUD/ADHD-SN patients in our study indicates this association is particularly evident with amphetamine.
Although previous studies report associations between ADHD and SUDs for other psychostimulants (e.g., cocaine) [8, 33] , it is unclear why concurrent ADHD symptoms were associated with increased amphetamine and not cocaine and ecstasy SUD prevalence.
However, these psychostimulant drugs act differentially on three primary neurotransmitter systems, eliciting discrete patterns of dopamine, norepinephrine, and serotonin transporter reuptake inhibition [58, 59] . These neurotransmitter receptors may function, be represented differently, or be differentially available in individuals with ADHD and thus, distinct neuropsychopharmacological interactions likely contribute to psychostimulant-specific behavioural reinforcement effects in these individuals [60, 61] . Furthermore, contrasting drugspecific modes of administration, duration of effect and pharmacokinetic properties (e.g., bioavailability, half-life) of these psychostimulants possibly interact with neurobiologicallyderived behavioural features associated with ADHD-related executive function deficits such as increased reward threshold, (i.e., requiring more immediacy, frequency and salience of reinforcers), impulse control and sensitisation induction [62] . However, the contribution of these factors to divergent psychostimulant dependence patterns cannot be ascertained with the current methodology and represent areas for future examination.
For drug-specific positive associations between ADHD screening status and reported history of SUD (i.e. amphetamine, alcohol, opiates other than heroin and methadone, and benzodiazepines), significant prevalence risk estimates attributable to ADHD symptom status occurred most frequently when SUD duration was ≥5 years. Although the association between ADHD screening status and discrete SUD duration levels has not been previously explored, the current findings corroborate previous assertions that comorbid ADHD results in longer SUD durations, i.e. a more chronic course of SUD [24] . Additionally, neuroimaging studies have identified biological links between ADHD and both SUD-craving brain activation 14 RUNNING HEAD: ADHD and Substance Use Disorder Complexity and SUD-impulsivity [53] , known risk factors for SUD persistence and the susceptibility to relapse [24, 54] . These findings imply that the identification of comorbid ADHD in SUD treatment settings may provide early indication of symptoms that may predict a greater risk of delayed SUD remission and SUD relapse. This may present clinicians with an opportunity to efficiently target, integrate, and implement treatment strategies addressing both conditions concurrently, shown to be more effective compared to parallel or segmented comorbid treatment approaches [26, 63] . Interestingly, the observed ADHD symptom-related increase in alcohol and benzodiazepine SUD duration raises the possibility that impaired executive functioning and behavioural inhibition may have particular relevance for these drug-specific SUD patterns. Prior research has postulated that reduced forebrain dopamine levels share a role in both ADHD-related executive deficits and alcohol SUD development [64] .
Benzodiazepines have been shown to alter reward threshold and behavioural inhibition [65] , both of which are associated with ADHD-related executive function deficits.
Our results indicate that SUD patients with comorbid ADHD symptoms report a pattern of increased SUD complexity and chronicity (i.e. experiencing more current SUDs, prior SUDs, and longer dependency) for amphetamine, alcohol, opiates other than heroin or methadone, and benzodiazepine drugs than ADHD-SN individuals with SUD. The ability to identify ADHD in SUD patients at treatment initiation may be advantageous in determining SUD patient characteristics that may place them at increased risk for poorer treatment outcomes.
Previous research has indicated that comorbid ADHD is a risk factor for extended SUD duration, slower remission rates, and a higher prevalence of substance-induced disorders, further complicating the treatment and management of SUD [22] [23] [24] . Given their accuracy, ease of administration, and time-effectiveness, screening tools such as the ASRS-6 may be especially efficacious for the detection of comorbid ADHD in drug treatment centre settings.
Therefore, not only could this assist the tailoring of SUD patient treatments but it may also enable additional integrated treatments of adult ADHD and SUD, representing a more holistic approach [26] . RUNNING HEAD: ADHD and Substance Use Disorder Complexity To our knowledge this study represents the largest assessment of the association between comorbid adult ADHD symptom status and drug-specific SUD complexity and chronicity while controlling for multiple confounders. Additionally, the ADHD-SP and drug-specific SUD associations discussed here remained significant after the Simes' correction was applied, further substantiating these inferences. However, some study limitations exist. The current study relied on participant self-reports which may impact on the data obtained; social acceptability, perceived consequences of disclosure, question comprehension, long-term recall duration and drug-related memory deficits are known factors influencing the accuracy of drug use self-reporting. Self-reported data, however, have been found to be sufficiently reliable and valid to inform about drug use patterns and associated problems [66, 67] and in the assessment of childhood and current symptoms of ADHD among adults [68] . The measure of SUD chronicity was derived from a proxy of self-reported 'problematic' regular drug use, however this measure is limited as it does not fully assess the drug dependence threshold for clinical impairment (i.e. withdrawal, increased tolerance, and impaired control).
Previous clinical diagnoses of CD and ODD were only assessed through binary self-report and as these diagnoses receive limited public attention in Australia, the recall of these diagnoses by participants is likely biased, resulting in the unusually low prevalence observed in the study group. Conversely, the possibility of patient-motivated ADHD diagnosis overreporting cannot be excluded. Additionally, as the study design was a cross-sectional survey, the temporal sequence of morbidity is not known. The fraction our sample represents of the total patients in the recruitment sites during the sampling period is also undetermined.
However, the current sample characteristics concord with Australian drug and alcohol treatment patients in regards to age, socioeconomic status, and drug requiring treatment [69] .
Finally, while a validated and widely-used tool in the literature, the ASRS-6 indicates ADHD symptom presence and does not definitively indicate ADHD diagnosis to the same extent as a clinical psychiatric examination. RUNNING HEAD: ADHD and Substance Use Disorder Complexity
CONCLUSION:
The findings of this study indicate that adult ADHD is highly overrepresented in treatmentseeking SUD populations as compared with their community counterparts in Australia.
Additionally, comorbid adult ADHD symptoms are associated with elevated drug dependence complexity and chronicity in treatment-seeking SUD populations, specifically for amphetamine, alcohol, opiates other than heroin and methadone, and benzodiazepines. The fact that this ADHD-related SUD pattern was observed in the current sample, where all participants had a severe current SUD necessitating treatment, is indicative of a robust association.
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